{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T13:50:06Z","timestamp":1790430606991,"version":"4.1.0"},"reference-count":170,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,17]],"date-time":"2023-03-17T00:00:00Z","timestamp":1679011200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81773557"],"award-info":[{"award-number":["81773557"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073690"],"award-info":[{"award-number":["82073690"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82173676"],"award-info":[{"award-number":["82173676"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273774"],"award-info":[{"award-number":["82273774"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2020YFA0908800"],"award-info":[{"award-number":["2020YFA0908800"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["2042021kf1033"],"award-info":[{"award-number":["2042021kf1033"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Insight"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.cellin.2023.100092","type":"journal-article","created":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T12:28:52Z","timestamp":1679920132000},"page":"100092","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":70,"title":["Antiviral PROTACs: Opportunity borne with challenge"],"prefix":"10.1016","volume":"2","author":[{"given":"Jinsen","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihe","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chune","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuwen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Bing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cellin.2023.100092_bib1","doi-asserted-by":"crossref","first-page":"4054","DOI":"10.1200\/JCO.2006.07.4658","article-title":"What is the right dose? The elusive optimal biologic dose in phase I clinical trials","volume":"24","author":"Adjei","year":"2006","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.cellin.2023.100092_bib2","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.3390\/v12101092","article-title":"Potential anti-SARS-CoV-2 therapeutics that target the post-entry stages of the viral life cycle: A comprehensive review","volume":"12","author":"Al-Horani","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.cellin.2023.100092_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127106","article-title":"Selective CDK6 degradation mediated by cereblon, VHL, and novel IAP-recruiting PROTACs","volume":"30","author":"Anderson","year":"2020","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"key":"10.1016\/j.cellin.2023.100092_bib4","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1111\/apt.14538","article-title":"The adverse effects of interferon-free regimens in 149 816 chronic hepatitis C treated Egyptian patients","volume":"47","author":"Attia","year":"2018","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1016\/j.cellin.2023.100092_bib5","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/s41586-020-2545-9","article-title":"Lysosome-targeting chimaeras for degradation of extracellular proteins","volume":"584","author":"Banik","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.cellin.2023.100092_bib6","doi-asserted-by":"crossref","first-page":"282","DOI":"10.2174\/187152607783018745","article-title":"Influenza viruses: Basic biology and potential drug targets","volume":"7","author":"Basler","year":"2007","journal-title":"Infectious Disorders: Drug Targets"},{"key":"10.1016\/j.cellin.2023.100092_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104488","article-title":"Drug repurposing for the treatment of COVID-19: Pharmacological aspects and synthetic approaches","volume":"106","author":"Batalha","year":"2021","journal-title":"Bioorganic Chemistry"},{"key":"10.1016\/j.cellin.2023.100092_bib8","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: The past is prologue","volume":"21","author":"Bekes","year":"2022","journal-title":"Nature Reviews Drug Discovery"},{"key":"10.1016\/j.cellin.2023.100092_bib9","article-title":"Ligandability of E3 ligases for targeted protein degradation applications","author":"Belcher","year":"2021","journal-title":"Biochemistry"},{"key":"10.1016\/j.cellin.2023.100092_bib10","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.bioorg.2018.08.028","article-title":"Discovery of Wogonin-based PROTACs against CDK9 and capable of achieving antitumor activity","volume":"81","author":"Bian","year":"2018","journal-title":"Bioorganic Chemistry"},{"key":"10.1016\/j.cellin.2023.100092_bib11","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.coviro.2021.09.009","article-title":"Drug resistance mutations in HIV: New bioinformatics approaches and challenges","volume":"51","author":"Blassel","year":"2021","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.cellin.2023.100092_bib12","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1001\/jama.295.8.joc60020","article-title":"Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States","volume":"295","author":"Bright","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.cellin.2023.100092_bib13","doi-asserted-by":"crossref","first-page":"o443","DOI":"10.1136\/bmj.o443","article-title":"Molnupiravir's authorisation was premature","volume":"376","author":"Brophy","year":"2022","journal-title":"BMJ"},{"key":"10.1016\/j.cellin.2023.100092_bib14","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1006\/viro.1993.1088","article-title":"Comparison of structure and sequence of influenza B\/yamagata and B\/beijing neuraminidases shows a conserved head but much greater variability in the stalk and Nb protein","volume":"192","author":"Burmeister","year":"1993","journal-title":"Virology"},{"key":"10.1016\/j.cellin.2023.100092_bib15","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abd5991","article-title":"Ribonuclease recruitment using a small molecule reduced c9ALS\/FTD r(G4C2) repeat expansion in vitro and in vivo ALS models","volume":"13","author":"Bush","year":"2021","journal-title":"Science Translational Medicine"},{"key":"10.1016\/j.cellin.2023.100092_bib16","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/s41589-021-00851-1","article-title":"Bifunctional small molecules that mediate the degradation of extracellular proteins","volume":"17","author":"Caianiello","year":"2021","journal-title":"Nature Chemical Biology"},{"key":"10.1016\/j.cellin.2023.100092_bib17","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/s41586-021-04387-1","article-title":"Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization","volume":"602","author":"Cele","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.cellin.2023.100092_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiomed.2022.105788","article-title":"In-silico screening and in-vitro assay show the antiviral effect of Indomethacin against SARS-CoV-2","volume":"147","author":"Chakraborty","year":"2022","journal-title":"Computers in Biology and Medicine"},{"key":"10.1016\/j.cellin.2023.100092_bib19","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.ejmech.2019.01.003","article-title":"Recent development of CDK inhibitors: An overview of CDK\/inhibitor co-crystal structures","volume":"164","author":"Cheng","year":"2019","journal-title":"European Journal of Medicinal Chemistry"},{"key":"10.1016\/j.cellin.2023.100092_bib20","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1021\/acs.jcim.1c01451","article-title":"Omicron variant (B.1.1.529): Infectivity, vaccine breakthrough, and antibody resistance","volume":"62","author":"Chen","year":"2022","journal-title":"Journal of Chemical Information and Modeling"},{"key":"10.1016\/j.cellin.2023.100092_bib21","doi-asserted-by":"crossref","first-page":"376","DOI":"10.3390\/cells8040376","article-title":"Hepatitis C virus infection: Host-virus interaction and mechanisms of viral persistence","volume":"8","author":"Chigbu","year":"2019","journal-title":"Cells-Basel"},{"key":"10.1016\/j.cellin.2023.100092_bib22","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/s12276-021-00608-9","article-title":"Emerging and re-emerging fatal viral diseases","volume":"53","author":"Choi","year":"2021","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.cellin.2023.100092_bib23","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1016\/j.cell.2017.10.033","article-title":"A\u00a0method for the acute and rapid degradation of endogenous proteins","volume":"171","author":"Clift","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.cellin.2023.100092_bib24","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1038\/s41596-018-0028-3","article-title":"Acute and rapid degradation of endogenous proteins by Trim-Away","volume":"13","author":"Clift","year":"2018","journal-title":"Nature Protocols"},{"key":"10.1016\/j.cellin.2023.100092_bib25","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1038\/nature06956","article-title":"Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants","volume":"453","author":"Collins","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.cellin.2023.100092_bib26","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1021\/jacs.0c10008","article-title":"Development of antibody-based PROTACs for the degradation of the cell-surface immune checkpoint protein PD-L1","volume":"143","author":"Cotton","year":"2021","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.cellin.2023.100092_bib27","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/s41568-021-00365-x","article-title":"Advancing targeted protein degradation for cancer therapy","volume":"21","author":"Dale","year":"2021","journal-title":"Nature Reviews Cancer"},{"key":"10.1016\/j.cellin.2023.100092_bib28","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1128\/CMR.00102-15","article-title":"Approved antiviral drugs over the past 50 years","volume":"29","author":"De Clercq","year":"2016","journal-title":"Clinical Microbiology Reviews"},{"key":"10.1016\/j.cellin.2023.100092_bib29","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1182\/blood.2019003604","article-title":"Selective inhibition of Ph-positive ALL cell growth through kinase-dependent and -independent effects by CDK6-specific PROTACs","volume":"135","author":"De Dominici","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.cellin.2023.100092_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113814","article-title":"Indomethacin-based PROTACs as pan-coronavirus antiviral agents","volume":"226","author":"Desantis","year":"2021","journal-title":"European Journal of Medicinal Chemistry"},{"key":"10.1016\/j.cellin.2023.100092_bib31","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.chembiol.2019.07.015","article-title":"RIBOTACs: Small molecules target RNA for degradation","volume":"26","author":"Dey","year":"2019","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.cellin.2023.100092_bib32","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1021\/acs.jmedchem.0c01845","article-title":"Antibody-mediated delivery of chimeric BRD4 degraders. Part 1: Exploration of antibody linker, payload loading, and payload molecular properties","volume":"64","author":"Dragovich","year":"2021","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.cellin.2023.100092_bib33","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1021\/acs.jcim.8b00872","article-title":"In silico modeling of PROTAC-mediated ternary complexes: Validation and application","volume":"59","author":"Drummond","year":"2019","journal-title":"Journal of Chemical Information and Modeling"},{"key":"10.1016\/j.cellin.2023.100092_bib34","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1007\/s40265-017-0830-1","article-title":"Middle East respiratory syndrome and severe acute respiratory syndrome: Current therapeutic options and potential targets for novel therapies","volume":"77","author":"Dyall","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.cellin.2023.100092_bib35","doi-asserted-by":"crossref","first-page":"672","DOI":"10.3390\/molecules26030672","article-title":"PROTACs and building blocks: The 2D chemical space in very early drug discovery","volume":"26","author":"Ermondi","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.cellin.2023.100092_bib37","doi-asserted-by":"crossref","first-page":"11454","DOI":"10.1021\/acs.jmedchem.2c00844","article-title":"Progress and challenges in targeted protein degradation for neurodegenerative disease therapy","volume":"65","author":"Fang","year":"2022","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.cellin.2023.100092_bib38","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1099\/vir.0.030494-0","article-title":"Recruitment of cyclin-dependent kinase 9 to nuclear compartments during cytomegalovirus late replication: Importance of an interaction between viral pUL69 and cyclin T1","volume":"92","author":"Feichtinger","year":"2011","journal-title":"Journal of General Virology"},{"key":"10.1016\/j.cellin.2023.100092_bib39","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S0140-6736(22)00152-0","article-title":"Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: Results of a systematic review and meta-regression","volume":"399","author":"Feikin","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.cellin.2023.100092_bib40","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jcv.2007.10.020","article-title":"Mutations of neuraminidase implicated in neuraminidase inhibitors resistance","volume":"41","author":"Ferraris","year":"2008","journal-title":"Journal of Clinical Virology"},{"key":"10.1016\/j.cellin.2023.100092_bib41","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1146\/annurev-virology-092818-015708","article-title":"Ebola virus: Pathogenesis and countermeasure development","volume":"6","author":"Furuyama","year":"2019","journal-title":"Annu. Rev. Virol."},{"key":"10.1016\/j.cellin.2023.100092_bib42","doi-asserted-by":"crossref","first-page":"28403","DOI":"10.1074\/jbc.R110.129809","article-title":"Influenza hemagglutinin and neuraminidase membrane glycoproteins","volume":"285","author":"Gamblin","year":"2010","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.cellin.2023.100092_bib43","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/liv.13304","article-title":"Future anti-HBV strategies","volume":"37","author":"Gane","year":"2017","journal-title":"Liver International"},{"key":"10.1016\/j.cellin.2023.100092_bib44","doi-asserted-by":"crossref","first-page":"4318","DOI":"10.1038\/s41467-022-32050-4","article-title":"Engineered bioorthogonal POLY-PROTAC nanoparticles for tumour-specific protein degradation and precise cancer therapy","volume":"13","author":"Gao","year":"2022","journal-title":"Nature Communications"},{"key":"10.1016\/j.cellin.2023.100092_bib45","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1021\/acsmedchemlett.9b00597","article-title":"PROTAC technology: Opportunities and challenges","volume":"11","author":"Gao","year":"2020","journal-title":"ACS Medicinal Chemistry Letters"},{"key":"10.1016\/j.cellin.2023.100092_bib46","doi-asserted-by":"crossref","first-page":"667","DOI":"10.3390\/v13040667","article-title":"Broad-spectrum antiviral strategies and nucleoside analogues","volume":"13","author":"Geraghty","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.cellin.2023.100092_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.mam.2021.101025","article-title":"Chaperone-mediated autophagy and disease: Implications for cancer and neurodegeneration","volume":"82","author":"G\u00f3mez-Sintes","year":"2021","journal-title":"Molecular Aspects of Medicine"},{"key":"10.1016\/j.cellin.2023.100092_bib48","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/fcp.12609","article-title":"Antiviral therapies: Advances and perspectives","volume":"35","author":"Goncalves","year":"2021","journal-title":"Fundamental & clinical Pharmacology"},{"key":"10.1016\/j.cellin.2023.100092_bib49","doi-asserted-by":"crossref","DOI":"10.1126\/science.abe9403","article-title":"Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms","volume":"370","author":"Gordon","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.cellin.2023.100092_bib50","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/s41586-020-2286-9","article-title":"A\u00a0SARS-CoV-2 protein interaction map reveals targets for drug repurposing","volume":"583","author":"Gordon","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.cellin.2023.100092_bib51","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1099\/jgv.0.000337","article-title":"New insight into the phosphorylation-regulated intranuclear localization of human cytomegalovirus pUL69 mediated by cyclin-dependent kinases (CDKs) and viral CDK orthologue pUL97","volume":"97","author":"Graf","year":"2016","journal-title":"Journal of General Virology"},{"key":"10.1016\/j.cellin.2023.100092_bib52","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222312858","article-title":"Development of a PROTAC-based targeting strategy provides a mechanistically unique mode of anti-cytomegalovirus activity","volume":"22","author":"Hahn","year":"2021","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.cellin.2023.100092_bib53","doi-asserted-by":"crossref","first-page":"5","DOI":"10.47287\/cen-09914-scicon1","article-title":"Arvinas unveils PROTAC structures","volume":"99","author":"Halford","year":"2021","journal-title":"Chemical & Engineering News"},{"key":"10.1016\/j.cellin.2023.100092_bib54","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1021\/acscentsci.0c00984","article-title":"Targeting the SARS-CoV-2 RNA genome with small molecule binders and ribonuclease targeting chimera (RIBOTAC) degraders","volume":"6","author":"Haniff","year":"2020","journal-title":"ACS Central Science"},{"key":"10.1016\/j.cellin.2023.100092_bib55","article-title":"Strategies for the discovery of oral PROTAC degraders aimed at cancer therapy","volume":"3","author":"Han","year":"2022","journal-title":"Cell Rep. Phys. Sci."},{"key":"10.1016\/j.cellin.2023.100092_bib56","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41392-022-00999-9","article-title":"PROTACs: Great opportunities for academia and industry (an update from 2020 to 2021)","volume":"7","author":"He","year":"2022","journal-title":"Signal Transduction and Targeted Therapy"},{"key":"10.1016\/j.cellin.2023.100092_bib57","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1056\/NEJMoa0807650","article-title":"Telaprevir and peginterferon with or without ribavirin for chronic HCV infection","volume":"360","author":"H\u00e9zode","year":"2009","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.cellin.2023.100092_bib58","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/nm.3253","article-title":"Regulation of hepatic innate immunity by hepatitis C virus","volume":"19","author":"Horner","year":"2013","journal-title":"Natura Med"},{"key":"10.1016\/j.cellin.2023.100092_bib59","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/nrg3922","article-title":"Evolutionary consequences of drug resistance: Shared principles across diverse targets and organisms","volume":"16","author":"Hughes","year":"2015","journal-title":"Nature Reviews Genetics"},{"key":"10.1016\/j.cellin.2023.100092_bib60","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1016\/j.drudis.2021.04.010","article-title":"Frontiers in PROTACs","volume":"26","author":"Hughes","year":"2021","journal-title":"Drug Discovery Today"},{"key":"10.1016\/j.cellin.2023.100092_bib61","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1021\/acs.jmedchem.8b01572","article-title":"Discovery of ERD-308 as a highly potent proteolysis targeting chimera (PROTAC) degrader of estrogen receptor (ER)","volume":"62","author":"Hu","year":"2019","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.cellin.2023.100092_bib62","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1128\/AAC.04534-14","article-title":"A\u00a0novel CDK7 inhibitor of the pyrazolotriazine class exerts broad-spectrum antiviral activity at nanomolar concentrations","volume":"59","author":"Hutterer","year":"2015","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.cellin.2023.100092_bib63","doi-asserted-by":"crossref","first-page":"6018","DOI":"10.1021\/jacs.7b01683","article-title":"Multivalent glycosylated nanostructures to inhibit Ebola virus infection","volume":"139","author":"Illescas","year":"2017","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.cellin.2023.100092_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104780","article-title":"Put a cork in it: Plugging the M2 viral ion channel to sink influenza","volume":"178","author":"Jalily","year":"2020","journal-title":"Antiviral Research"},{"key":"10.1016\/j.cellin.2023.100092_bib65","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/s41586-021-03990-6","article-title":"A\u00a0pan-serotype dengue virus inhibitor targeting the NS3\u2013NS4B interaction","volume":"598","author":"Kaptein","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.cellin.2023.100092_bib66","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/s41586-022-04429-2","article-title":"Structure and receptor recognition by the Lassa virus spike complex","volume":"603","author":"Katz","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.cellin.2023.100092_bib67","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1038\/s41591-019-0668-z","article-title":"A\u00a0selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity","volume":"25","author":"Khan","year":"2019","journal-title":"Natura Med"},{"key":"10.1016\/j.cellin.2023.100092_bib68","doi-asserted-by":"crossref","first-page":"890","DOI":"10.5009\/gnl15573","article-title":"Hepatitis C virus and antiviral drug resistance","volume":"10","author":"Kim","year":"2016","journal-title":"Gut Liver"},{"key":"10.1016\/j.cellin.2023.100092_bib69","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.chom.2022.06.008","article-title":"The logic of virus evolution","volume":"30","author":"Koonin","year":"2022","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.cellin.2023.100092_bib70","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2174\/1389450023347650","article-title":"Hepatitis C virus proteins as targets for drug development: The role of bioinformatics and modelling","volume":"3","author":"Lahm","year":"2002","journal-title":"Current Drug Targets"},{"key":"10.1016\/j.cellin.2023.100092_bib71","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1042\/EBC20170035","article-title":"Regulation of selective autophagy: The p62\/SQSTM1 paradigm","volume":"61","author":"Lamark","year":"2017","journal-title":"Essays in Biochemistry"},{"key":"10.1016\/j.cellin.2023.100092_bib72","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s40265-020-01378-w","article-title":"Remdesivir: First approval","volume":"80","author":"Lamb","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.cellin.2023.100092_bib73","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s40265-022-01692-5","article-title":"Nirmatrelvir plus ritonavir: First approval","volume":"82","author":"Lamb","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.cellin.2023.100092_bib74","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/s41467-022-28603-2","article-title":"Secondary structural ensembles of the SARS-CoV-2 RNA genome in infected cells","volume":"13","author":"Lan","year":"2022","journal-title":"Nature Communications"},{"key":"10.1016\/j.cellin.2023.100092_bib75","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.bioorg.2016.06.005","article-title":"3-Substituted-4-hydroxycoumarin as a new scaffold with potent CDK inhibition and promising anticancer effect: Synthesis, molecular modeling and QSAR studies","volume":"67","author":"Latif","year":"2016","journal-title":"Bioorganic Chemistry"},{"key":"10.1016\/j.cellin.2023.100092_bib76","doi-asserted-by":"crossref","first-page":"6515","DOI":"10.3390\/molecules27196515","article-title":"Discovery of E3 ligase ligands for target protein degradation","volume":"27","author":"Lee","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.cellin.2023.100092_bib77","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3851\/IMP1684","article-title":"Nanoparticulate delivery systems for antiviral drugs","volume":"21","author":"Lembo","year":"2010","journal-title":"Antiviral Chemistry & Chemotherapy"},{"key":"10.1016\/j.cellin.2023.100092_bib78","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cell.2018.09.048","article-title":"Biological functions of autophagy genes: A disease perspective","volume":"176","author":"Levine","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.cellin.2023.100092_bib79","first-page":"2105","volume":"85","author":"Liang","year":"2020","journal-title":"Advances in Antiviral Material Development. Chempluschem."},{"key":"10.1016\/j.cellin.2023.100092_bib80","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/s41579-021-00536-5","article-title":"The human virome: Assembly, composition and host interactions","volume":"19","author":"Liang","year":"2021","journal-title":"Nature Reviews Microbiology"},{"key":"10.1016\/j.cellin.2023.100092_bib81","first-page":"1","article-title":"Enzyme-catalyzed activation of pro-PROTAC for cell-selective protein degradation","author":"Liang","year":"2022","journal-title":"CCS Chemistry"},{"key":"10.1016\/j.cellin.2023.100092_bib82","doi-asserted-by":"crossref","first-page":"7133","DOI":"10.1038\/s41467-022-34807-3","article-title":"DeepPROTACs is a deep learning-based targeted degradation predictor for PROTACs","volume":"13","author":"Li","year":"2022","journal-title":"Nature Communications"},{"key":"10.1016\/j.cellin.2023.100092_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2020.170328","article-title":"In silico design of antiviral peptides targeting the spike protein of SARS-CoV-2","volume":"130","author":"Ling","year":"2020","journal-title":"Peptides"},{"key":"10.1016\/j.cellin.2023.100092_bib84","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.nbd.2018.05.010","article-title":"Chaperone-mediated autophagy: Advances from bench to bedside","volume":"122","author":"Li","year":"2019","journal-title":"Neurobiology of Disease"},{"key":"10.1016\/j.cellin.2023.100092_bib85","doi-asserted-by":"crossref","first-page":"17508","DOI":"10.1074\/jbc.M313020200","article-title":"In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: Structural analysis indicates different resistance mechanisms","volume":"279","author":"Lin","year":"2004","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.cellin.2023.100092_bib86","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.3389\/fmicb.2018.02325","article-title":"Antiviral agents from fungi: Diversity, mechanisms and potential applications","volume":"9","author":"Linnakoski","year":"2018","journal-title":"Frontiers in Microbiology"},{"key":"10.1016\/j.cellin.2023.100092_bib87","doi-asserted-by":"crossref","first-page":"303","DOI":"10.3389\/fonc.2018.00303","article-title":"Targeting cyclin-dependent kinases for treatment of gynecologic cancers","volume":"8","author":"Lin","year":"2018","journal-title":"Frontiers Oncology"},{"key":"10.1016\/j.cellin.2023.100092_bib88","doi-asserted-by":"crossref","first-page":"10183","DOI":"10.1021\/acs.jmedchem.2c00691","article-title":"Targeting undruggable transcription factors with PROTACs: Advances and perspectives","volume":"65","author":"Li","year":"2022","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.cellin.2023.100092_bib89","doi-asserted-by":"crossref","first-page":"16930","DOI":"10.1021\/jacs.2c05499","article-title":"Discovery of XL01126: A potent, fast, cooperative, selective, orally bioavailable, and blood-brain barrier penetrant PROTAC degrader of leucine-rich repeat kinase 2","volume":"144","author":"Liu","year":"2022","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.cellin.2023.100092_bib90","doi-asserted-by":"crossref","first-page":"7154","DOI":"10.1021\/acs.jmedchem.1c02013","article-title":"Discovery of pentacyclic triterpenoid PROTACs as a class of effective hemagglutinin protein degraders","volume":"65","author":"Li","year":"2022","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.cellin.2023.100092_bib91","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41586-019-1722-1","article-title":"Allele-selective lowering of mutant HTT protein by HTT-LC3 linker compounds","volume":"575","author":"Li","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.cellin.2023.100092_bib92","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1080\/15548627.2019.1688556","article-title":"ATTEC: A potential new approach to target proteinopathies","volume":"16","author":"Li","year":"2020","journal-title":"Autophagy"},{"key":"10.1016\/j.cellin.2023.100092_bib93","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1016\/S0140-6736(12)61728-0","article-title":"Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the global burden of disease study 2010","volume":"380","author":"Lozano","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.cellin.2023.100092_bib94","doi-asserted-by":"crossref","first-page":"17098","DOI":"10.1021\/acs.jmedchem.1c01069","article-title":"Targeting of the FOXM1 oncoprotein by E3 ligase-assisted degradation","volume":"64","author":"Luo","year":"2021","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.cellin.2023.100092_bib95","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/s41586-022-05235-6","article-title":"Antibody targeting of E3 ubiquitin ligases for receptor degradation","volume":"610","author":"Marei","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.cellin.2023.100092_bib96","doi-asserted-by":"crossref","DOI":"10.1111\/ijcp.13535","article-title":"Indomethacin and resveratrol as potential treatment adjuncts for SARS-CoV-2\/COVID-19","volume":"74","author":"Marinella","year":"2020","journal-title":"International Journal of Clinical Practice"},{"key":"10.1016\/j.cellin.2023.100092_bib97","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2021-1265","article-title":"Abstract 1265: Discovery of GT19077, a c-Myc\/Max protein-protein Interaction (PPI) small molecule inhibitor, and GT19506 a c-Myc PROTAC molecule, for targeting c-Myc-driven blood cancers and small cell lung cancers","volume":"81","author":"Ma","year":"2021","journal-title":"Cancer Research"},{"key":"10.1016\/j.cellin.2023.100092_bib98","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1021\/acs.chemrev.0c00648","article-title":"Drug design strategies to avoid resistance in direct-acting antivirals and beyond","volume":"121","author":"Matthew","year":"2021","journal-title":"Chemical Reviews"},{"key":"10.1016\/j.cellin.2023.100092_bib99","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.coph.2016.07.015","article-title":"Hepatitis C virus NS3\/4a protease inhibitors","volume":"30","author":"McCauley","year":"2016","journal-title":"Current Opinion in Pharmacology"},{"key":"10.1016\/j.cellin.2023.100092_bib100","doi-asserted-by":"crossref","first-page":"21096","DOI":"10.1021\/jacs.2c07217","article-title":"DNA-encoded library screening to inform design of a ribonuclease targeting chimera (RiboTAC)","volume":"144","author":"Meyer","year":"2022","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.cellin.2023.100092_bib101","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.virusres.2014.11.021","article-title":"Host cell proteases: Critical determinants of coronavirus tropism and pathogenesis","volume":"202","author":"Millet","year":"2015","journal-title":"Virus Research"},{"key":"10.1016\/j.cellin.2023.100092_bib102","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/nature03063","article-title":"Transmissibility of 1918 pandemic influenza","volume":"432","author":"Mills","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.cellin.2023.100092_bib103","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.bbrc.2014.10.006","article-title":"Design of a PROTAC that antagonizes and destroys the cancer-forming X-protein of the hepatitis B virus","volume":"453","author":"Montrose","year":"2014","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1016\/j.cellin.2023.100092_bib104","doi-asserted-by":"crossref","DOI":"10.1126\/science.aaw8977","article-title":"Diverse variola virus (smallpox) strains were widespread in northern Europe in the Viking Age","volume":"369","author":"M\u00fchlemann","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.cellin.2023.100092_bib105","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02221-18","article-title":"Validating enterovirus D68-2apro as an antiviral drug target and the discovery of telaprevir as a potent D68-2apro inhibitor","volume":"93","author":"Musharrafieh","year":"2019","journal-title":"Journal of Virology"},{"key":"10.1016\/j.cellin.2023.100092_bib106","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1136\/archdischild-2016-312043","article-title":"Hepatitis B: Changing epidemiology and interventions","volume":"102","author":"Nannini","year":"2017","journal-title":"Archives of Disease in Childhood"},{"key":"10.1016\/j.cellin.2023.100092_bib107","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1200\/JCO.2019.37.7_suppl.259","article-title":"ARV-110: An oral androgen receptor PROTAC degrader for prostate cancer","volume":"37","author":"Neklesa","year":"2019","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.cellin.2023.100092_bib108","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2018-5236","article-title":"Abstract 5236: ARV-110: An androgen receptor PROTAC degrader for prostate cancer","volume":"78","author":"Neklesa","year":"2018","journal-title":"Cancer Research"},{"key":"10.1016\/j.cellin.2023.100092_bib109","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12943-022-01535-7","article-title":"Clinical considerations for the design of PROTACs in cancer","volume":"21","author":"Nieto-Jimenez","year":"2022","journal-title":"Molecular Cancer"},{"key":"10.1016\/j.cellin.2023.100092_bib110","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.114012","article-title":"Noncovalent CDK12\/13 dual inhibitors-based PROTACs degrade CDK12-Cyclin K complex and induce synthetic lethality with PARP inhibitor","volume":"228","author":"Niu","year":"2022","journal-title":"European Journal of Medicinal Chemistry"},{"key":"10.1016\/j.cellin.2023.100092_bib111","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/nchembio.2538","article-title":"Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation","volume":"14","author":"Olson","year":"2018","journal-title":"Nature Chemical Biology"},{"key":"10.1016\/j.cellin.2023.100092_bib112","first-page":"2215","article-title":"Cellular resistance mechanisms to targeted protein degradation converge toward impairment of the engaged ubiquitin transfer pathway","volume":"14","author":"Ottis","year":"2019","journal-title":"ACS Chemical Biology"},{"key":"10.1016\/j.cellin.2023.100092_bib113","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1021\/acs.jnatprod.6b00878","article-title":"Metabolites from the plant endophytic fungus Aspergillus sp CPCC 400735 and their anti-HIV activities","volume":"80","author":"Pang","year":"2017","journal-title":"Journal of Natural Products"},{"key":"10.1016\/j.cellin.2023.100092_bib114","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1002\/hep.32241","article-title":"Risk of HBV reactivation during therapies for HCC: A systematic review","volume":"75","author":"Papatheodoridi","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.cellin.2023.100092_bib115","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/s41551-020-00658-w","article-title":"Development of vaccines and antivirals for combating viral pandemics","volume":"4","author":"Pardi","year":"2020","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.cellin.2023.100092_bib116","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ddtec.2019.01.002","article-title":"PROteolysis TArgeting Chimeras (PROTACs) - past, present and future","volume":"31","author":"Pettersson","year":"2019","journal-title":"Drug Discovery Today: Technologies"},{"key":"10.1016\/j.cellin.2023.100092_bib117","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1021\/acscentsci.9b00713","article-title":"Reversible spatiotemporal control of induced protein degradation by bistable PhotoPROTACs","volume":"5","author":"Pfaff","year":"2019","journal-title":"ACS Central Science"},{"key":"10.1016\/j.cellin.2023.100092_bib118","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.107940","article-title":"Remdesivir inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice","volume":"32","author":"Pruijssers","year":"2020","journal-title":"Cell Reports"},{"key":"10.1016\/j.cellin.2023.100092_bib119","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-19679-3","article-title":"Evaluating immunogenicity of pathogen-derived T-cell epitopes to design a peptide-based smallpox vaccine","volume":"12","author":"Quach","year":"2022","journal-title":"Scientific Reports"},{"key":"10.1016\/j.cellin.2023.100092_bib120","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1146\/annurev-virology-100114-055238","article-title":"Virus-host interactions: From unbiased genetic screens to function","volume":"2","author":"Ramage","year":"2015","journal-title":"Annu. Rev. Virol."},{"key":"10.1016\/j.cellin.2023.100092_bib121","author":"Rangan"},{"key":"10.1016\/j.cellin.2023.100092_bib122","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.3390\/ph3051530","article-title":"Nonsteroidal anti-inflammatory drugs (NSAIDs): Progress in small molecule drug development","volume":"3","author":"Rao","year":"2010","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.cellin.2023.100092_bib123","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/jps.2600530836","article-title":"Idoxuridine\u2014a preliminary report","volume":"53","author":"Ravin","year":"1964","journal-title":"Journal of Pharmaceutical Sciences"},{"key":"10.1016\/j.cellin.2023.100092_bib124","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aay5064","article-title":"PHOTACs enable optical control of protein degradation","volume":"6","author":"Reynders","year":"2020","journal-title":"Science Advances"},{"key":"10.1016\/j.cellin.2023.100092_bib125","doi-asserted-by":"crossref","first-page":"7577","DOI":"10.1039\/C7CC03879H","article-title":"Chemically induced degradation of CDK9 by a proteolysis targeting chimera (PROTAC)","volume":"53","author":"Robb","year":"2017","journal-title":"Chem. Commun. (Camb)."},{"key":"10.1016\/j.cellin.2023.100092_bib126","doi-asserted-by":"crossref","first-page":"5438","DOI":"10.1021\/acs.jcim.1c01135","article-title":"pdCSM-PPI: Using graph-based signatures to identify protein-protein interaction inhibitors","volume":"61","author":"Rodrigues","year":"2021","journal-title":"Journal of Chemical Information and Modeling"},{"key":"10.1016\/j.cellin.2023.100092_bib127","doi-asserted-by":"crossref","first-page":"7201","DOI":"10.1038\/onc.2008.320","article-title":"Targeting steroid hormone receptors for ubiquitination and degradation in breast and prostate cancer","volume":"27","author":"Rodriguez-Gonzalez","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.cellin.2023.100092_bib128","doi-asserted-by":"crossref","first-page":"8554","DOI":"10.1073\/pnas.141230798","article-title":"Protacs: Chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation","volume":"98","author":"Sakamoto","year":"2001","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.cellin.2023.100092_bib129","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1053\/j.gastro.2007.02.037","article-title":"Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir","volume":"132","author":"Sarrazin","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cellin.2023.100092_bib130","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2144\/btn-2020-0134","article-title":"Developing drugs for the \u2018undruggable\u2019","volume":"69","author":"Sawyer","year":"2020","journal-title":"Biotechniques"},{"key":"10.1016\/j.cellin.2023.100092_bib131","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009312","article-title":"Evidence for distinct mechanisms of small molecule inhibitors of filovirus entry","volume":"17","author":"Schafer","year":"2021","journal-title":"PLoS Pathogens"},{"key":"10.1016\/j.cellin.2023.100092_bib132","doi-asserted-by":"crossref","first-page":"618","DOI":"10.3390\/v12060618","article-title":"The dynamic life of virus capsids","volume":"12","author":"Sherman","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.cellin.2023.100092_bib133","doi-asserted-by":"crossref","first-page":"5057","DOI":"10.1021\/acs.jmedchem.1c02221","article-title":"Rational design for nitroreductase (NTR)-Responsive proteolysis targeting chimeras (PROTACs) selectively targeting tumor tissues","volume":"65","author":"Shi","year":"2022","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.cellin.2023.100092_bib134","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1016\/j.chembiol.2022.08.004","article-title":"Target protein localization and its impact on PROTAC-mediated degradation","volume":"29","author":"Simpson","year":"2022","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.cellin.2023.100092_bib135","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/s41587-022-01381-4","article-title":"Generation of a live attenuated influenza A vaccine by proteolysis targeting","volume":"40","author":"Si","year":"2022","journal-title":"Nature Biotechnology"},{"key":"10.1016\/j.cellin.2023.100092_bib136","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1146\/annurev.med.56.091103.134135","article-title":"Severe acute respiratory syndrome (SARS): A year in review","volume":"56","author":"Skowronski","year":"2005","journal-title":"Annual Review of Medicine"},{"key":"10.1016\/j.cellin.2023.100092_bib137","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.antiviral.2018.11.008","article-title":"In vivo proof-of-concept for two experimental antiviral drugs, both directed to cellular targets, using a murine cytomegalovirus model","volume":"161","author":"Sonntag","year":"2019","journal-title":"Antiviral Research"},{"key":"10.1016\/j.cellin.2023.100092_bib138","doi-asserted-by":"crossref","first-page":"3487","DOI":"10.1039\/D2CS00148A","article-title":"E3 ligase ligand chemistries: From building blocks to protein degraders","volume":"51","author":"Sosic","year":"2022","journal-title":"Chemical Society Reviews"},{"key":"10.1016\/j.cellin.2023.100092_bib139","doi-asserted-by":"crossref","DOI":"10.1002\/adfm.202010556","article-title":"Nanogel-facilitated protein intracellular specific degradation through trim-away","volume":"31","author":"Sui","year":"2021","journal-title":"Advanced Functional Materials"},{"key":"10.1016\/j.cellin.2023.100092_bib140","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.jinf.2019.10.020","article-title":"Transmitted and acquired oseltamivir resistance during the 2018-2019 influenza season","volume":"79","author":"Tang","year":"2019","journal-title":"Journal of Infection"},{"key":"10.1016\/j.cellin.2023.100092_bib141","doi-asserted-by":"crossref","first-page":"9299","DOI":"10.1021\/jacs.8b05807","article-title":"3-Fluoro-4-hydroxyprolines: Synthesis, conformational analysis, and stereoselective recognition by the VHL E3 ubiquitin ligase for targeted protein degradation","volume":"140","author":"Testa","year":"2018","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.cellin.2023.100092_bib142","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ejmech.2016.04.008","article-title":"Progress and prospects on DENV protease inhibitors","volume":"117","author":"Timiri","year":"2016","journal-title":"European Journal of Medicinal Chemistry"},{"key":"10.1016\/j.cellin.2023.100092_bib143","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.ijbiomac.2021.01.076","article-title":"Trends and strategies to combat viral infections: A review on FDA approved antiviral drugs","volume":"172","author":"Tompa","year":"2021","journal-title":"International Journal of Biological Macromolecules"},{"key":"10.1016\/j.cellin.2023.100092_bib144","doi-asserted-by":"crossref","first-page":"9188","DOI":"10.1038\/s41598-022-13373-0","article-title":"The impact of the suppression of highly connected protein interactions on the corona virus infection","volume":"12","author":"Torres","year":"2022","journal-title":"Scientific Reports"},{"key":"10.1016\/j.cellin.2023.100092_bib145","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0236447","article-title":"OCIAD1 is a host mitochondrial substrate of the hepatitis C virus NS3-4A protease","volume":"15","author":"Tran","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.cellin.2023.100092_bib146","doi-asserted-by":"crossref","first-page":"714","DOI":"10.3390\/vaccines10050714","article-title":"Influenza viruses and vaccines: The role of vaccine effectiveness studies for evaluation of the benefits of influenza vaccines","volume":"10","author":"Trombetta","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.cellin.2023.100092_bib147","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1021\/acs.jmedchem.6b01115","article-title":"Binding and proton blockage by amantadine variants of the influenza M2WT and M2S31N explained","volume":"60","author":"Tzitzoglaki","year":"2017","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.cellin.2023.100092_bib148","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/303035a0","article-title":"Structure of the influenza-virus glycoprotein antigen neuraminidase at 2.9-a-Resolution","volume":"303","author":"Varghese","year":"1983","journal-title":"Nature"},{"key":"10.1016\/j.cellin.2023.100092_bib149","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.3390\/v3101933","article-title":"Viral ancestors of antiviral systems","volume":"3","author":"Villarreal","year":"2011","journal-title":"Viruses"},{"key":"10.1016\/j.cellin.2023.100092_bib150","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/s41589-018-0161-x","article-title":"HIP1R targets PD-L1 to lysosomal degradation to alter T cell-mediated cytotoxicity","volume":"15","author":"Wang","year":"2019","journal-title":"Nature Chemical Biology"},{"key":"10.1016\/j.cellin.2023.100092_bib151","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114711","article-title":"The current strategies of optimization of oseltamivir against mutant neuraminidases of influenza AA review","volume":"243","author":"Wang","year":"2022","journal-title":"European Journal of Medicinal Chemistry"},{"key":"10.1016\/j.cellin.2023.100092_bib152","doi-asserted-by":"crossref","first-page":"14822","DOI":"10.1021\/acs.jmedchem.1c01350","article-title":"Discovery of potent and selective CDK9 degraders for targeting transcription regulation in triple-negative breast cancer","volume":"64","author":"Wei","year":"2021","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.cellin.2023.100092_bib153","doi-asserted-by":"crossref","first-page":"16271","DOI":"10.1021\/acs.jmedchem.1c01576","article-title":"Integrative modeling of PROTAC-mediated ternary complexes","volume":"64","author":"Weng","year":"2021","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.cellin.2023.100092_bib154","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1093\/nar\/gkaa807","article-title":"PROTAC-DB: An online database of PROTACs","volume":"49","author":"Weng","year":"2021","journal-title":"Nucleic Acids Research"},{"key":"10.1016\/j.cellin.2023.100092_bib156","doi-asserted-by":"crossref","first-page":"575","DOI":"10.3390\/ijms22020575","article-title":"Combinatorial drug treatments reveal promising anticytomegaloviral profiles for clinically relevant pharmaceutical kinase inhibitors (PKIs)","volume":"22","author":"Wild","year":"2021","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.cellin.2023.100092_bib157","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1038\/s41467-019-11429-w","article-title":"Small molecule degraders of the hepatitis C virus protease reduce susceptibility to resistance mutations","volume":"10","author":"de Wispelaere","year":"2019","journal-title":"Nature Communications"},{"key":"10.1016\/j.cellin.2023.100092_bib158","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3390\/vaccines9030190","article-title":"Development of pandemic vaccines: ERVEBO case study","volume":"9","author":"Wolf","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.cellin.2023.100092_bib159","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.lfs.2018.04.051","article-title":"The role of HBV-induced autophagy in HBV replication and HBV related-HCC","volume":"205","author":"Xie","year":"2018","journal-title":"Life Sciences"},{"key":"10.1016\/j.cellin.2023.100092_bib160","doi-asserted-by":"crossref","first-page":"22622","DOI":"10.1021\/jacs.2c09255","article-title":"Bridged proteolysis targeting chimera (PROTAC) enables degradation of undruggable targets","volume":"144","author":"Xiong","year":"2022","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.cellin.2023.100092_bib161","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellin.2022.100030","article-title":"Discovery of oseltamivir-based novel PROTACs as degraders targeting neuraminidase to combat H1N1 influenza virus","volume":"1","author":"Xu","year":"2022","journal-title":"Cell Insight"},{"key":"10.1016\/j.cellin.2023.100092_bib162","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1002\/med.21763","article-title":"Drug repurposing approach to combating coronavirus: Potential drugs and drug targets","volume":"41","author":"Xu","year":"2021","journal-title":"Medicinal Research Reviews"},{"key":"10.1016\/j.cellin.2023.100092_bib163","doi-asserted-by":"crossref","DOI":"10.1021\/acsinfecdis.1c00271","article-title":"Antiviral therapeutics","volume":"7","author":"Yang","year":"2021","journal-title":"ACS Infectious Diseases"},{"key":"10.1016\/j.cellin.2023.100092_bib164","doi-asserted-by":"crossref","first-page":"6833","DOI":"10.7150\/thno.59020","article-title":"A\u00a0nano-predator of pathological MDMX construct by clearable supramolecular gold(I)-thiol-peptide complexes achieves safe and potent anti-tumor activity","volume":"11","author":"Yan","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.cellin.2023.100092_bib165","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112981","article-title":"Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: Recent progress and future challenges","volume":"210","author":"Zeng","year":"2021","journal-title":"European Journal of Medicinal Chemistry"},{"key":"10.1016\/j.cellin.2023.100092_bib166","doi-asserted-by":"crossref","first-page":"4624","DOI":"10.1021\/acs.jproteome.0c00316","article-title":"Repurpose open data to discover therapeutics for COVID-19 using deep learning","volume":"19","author":"Zeng","year":"2020","journal-title":"Journal of Proteome Research"},{"key":"10.1016\/j.cellin.2023.100092_bib167","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/s41589-019-0279-5","article-title":"Electrophilic PROTACs that degrade nuclear proteins by engaging DCAF16","volume":"15","author":"Zhang","year":"2019","journal-title":"Nature Chemical Biology"},{"key":"10.1016\/j.cellin.2023.100092_bib168","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.3389\/fmicb.2017.02286","article-title":"Modulation of lipid droplet metabolism-A potential target for therapeutic intervention in flaviviridae infections","volume":"8","author":"Zhang","year":"2017","journal-title":"Frontiers in Microbiology"},{"key":"10.1016\/j.cellin.2023.100092_bib169","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1158\/1535-7163.MCT-18-1129","article-title":"Acquired resistance to BET-PROTACs (Proteolysis-Targeting chimeras) caused by genomic alterations in core components of E3 ligase complexes","volume":"18","author":"Zhang","year":"2019","journal-title":"Molecular Cancer Therapeutics"},{"key":"10.1016\/j.cellin.2023.100092_bib170","doi-asserted-by":"crossref","first-page":"14765","DOI":"10.1039\/C9CC07217A","article-title":"Utilizing PROTAC technology to address the on-target platelet toxicity associated with inhibition of BCL-XL","volume":"55","author":"Zhang","year":"2019","journal-title":"Chem. Commun. (Camb)."},{"key":"10.1016\/j.cellin.2023.100092_bib171","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1038\/s41467-021-23194-w","article-title":"Semiconducting polymer nano-PROTACs for activatable photo-immunometabolic cancer therapy","volume":"12","author":"Zhang","year":"2021","journal-title":"Nature Communications"},{"key":"10.1016\/j.cellin.2023.100092_bib172","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1038\/s41467-022-29690-x","article-title":"An anti-influenza A virus microbial metabolite acts by degrading viral endonuclease PA","volume":"13","author":"Zhao","year":"2022","journal-title":"Nature Communications"}],"updated-by":[{"DOI":"10.1016\/j.cellin.2024.100225","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000}}],"container-title":["Cell Insight"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772892723000160?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772892723000160?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T13:25:23Z","timestamp":1757424323000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772892723000160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":170,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S2772892723000160"],"URL":"https:\/\/doi.org\/10.1016\/j.cellin.2023.100092","relation":{},"ISSN":["2772-8927"],"issn-type":[{"value":"2772-8927","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antiviral PROTACs: Opportunity borne with challenge","name":"articletitle","label":"Article Title"},{"value":"Cell Insight","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cellin.2023.100092","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V. on behalf of Wuhan University.","name":"copyright","label":"Copyright"}],"article-number":"100092"}}